Name (Synonyms) | Correlation | |
---|---|---|
drug821 | Tele-medicine platform Wiki | 0.71 |
drug17 | 2D Telemedicine Wiki | 0.71 |
drug703 | Rivaroxaban 2.5 MG Wiki | 0.71 |
drug12 | 2: No instruction regarding positioning Wiki | 0.71 |
drug206 | Clopidogrel 75mg Wiki | 0.71 |
drug71 | Atorvastatin 40mg Wiki | 0.71 |
drug8 | 1: Prone positioning Wiki | 0.71 |
drug65 | Aspirin 75mg Wiki | 0.71 |
drug576 | Omeprazole 20mg Wiki | 0.71 |
drug18 | 3D Telemedicine Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D054143 | Heart Failure, Systolic NIH | 0.71 |
D000787 | Angina Pectoris NIH | 0.71 |
D006333 | Heart Failure NIH | 0.71 |
D003327 | Coronary Disease NIH | 0.71 |
D003324 | Coronary Artery Disease NIH | 0.50 |
D009203 | Myocardial Ischemia NIH | 0.41 |
D002318 | Cardiovascular Diseases NIH | 0.21 |
D013577 | Syndrome NIH | 0.11 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.
Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context
Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients Time: 6 monthsDescription: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);
Measure: Number of patients included in this platform Time: 6 monthsDescription: Will be the number of sessions per patient multiplied with the number of patients included
Measure: Number of consultations/sessions given Time: 6 monthsThe outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. At the time of writing, there have been 150 000 confirmed cases and 3500 deaths. Apart from the morbidity and mortality directly related to COVID-19 cases, society has had to also cope with complex political and economic repercussions of this disease. At present, and despite pressing need for therapeutic intervention, management of patients with COVID-19 is entirely supportive. Despite the majority of patients experiencing a mild respiratory illness a subgroup, and in particular those with pre-existing cardiovascular disease, will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit. Furthermore, the severity of COVID-19 disease (as well as the likelihood of progressing to severe disease) appears to be in part driven by direct injury to the cardiovascular system. Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease. The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear. There is however mounting evidence that heart attack like events are responsible. Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients. Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease. It will also help us determine if there is more we can do to treat these patients.
Description: All-cause mortality
Measure: All-cause mortality at 30 days after admission Time: at 30 days after admissionDescription: Absolute change in serum troponin from admission (or from suspicion/diagnosis of Covid-19 if already an inpatient) measurement to peak value (measured using high sensitivity troponin assay). (Phase I interim analysis)
Measure: Absolute change in serum troponin from admission to peak value Time: within 7 days and within 30 days of admissionDescription: Discharge Rate: Proportion of patients discharged (or documented as medically fit for discharge)
Measure: Discharge Rate Time: at 7 days and 30 days after admissionDescription: Intubation Rate: Proportion of patients who have been intubated for mechanical ventilation
Measure: Intubation Rate Time: at 7 days and at 30 days after admission